Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, ...

Medicinal active agents are based on the universal concept of target recognition. Their history is characterized by a limited number of revolutionary advances. The Paul Ehrlich ‘lock and key’ ...

In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

On Thursday, September 4, 2025, Codexis (NASDAQ:CDXS) presented at the Cantor Global Healthcare Conference, outlining its strategic focus on enzymatic synthesis for siRNA therapeutics. The company ...

“The copious patentable aspects of a therapeutically efficacious siRNA delivery formulation imply intense patenting activity in the years to come, along with market exclusivity that can be extended ...

Bayer & Soufflé Therapeutics enter strategic collaboration to advance cell-specific heart-targeted siRNA therapy: Berlin, Germany Friday, January 9, 2026, 09:00 Hrs [IST] Bayer a ...